Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake

Dow Jones03-13

By Denny Jacob

Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.

Acelyrin said Tang Capital held 8.8% of its outstanding common stock.

Tang Capital didn't immediately respond to a request for comment issued through LinkedIn.

Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount.

Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at $3 a share.

Concentra's all-cash proposal, which includes a right to receive 80% of proceeds from any out-license or disposition of Acelyrin's development programs or intellectual property, came after Acelyrin agreed earlier in the month to merge with Alumis in an all-stock deal that is expected to close in the second quarter.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

March 13, 2025 08:15 ET (12:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2519350938?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-13 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519350938","market":"fut","top_or_hot":-1,"title":"Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company. \n</p>\n<p>\n  The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock. \n</p>\n<p>\n  Acelyrin said Tang Capital held 8.8% of its outstanding common stock. \n</p>\n<p>\n  Tang Capital didn't immediately respond to a request for comment issued through LinkedIn. \n</p>\n<p>\n  Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount. \n</p>\n<p>\n  Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at $3 a share. \n</p>\n<p>\n  Concentra's all-cash proposal, which includes a right to receive 80% of proceeds from any out-license or disposition of Acelyrin's development programs or intellectual property, came after Acelyrin agreed earlier in the month to merge with Alumis in an all-stock deal that is expected to close in the second quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 13, 2025 08:15 ET (12:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-13 20:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company. \n</p>\n<p>\n  The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock. \n</p>\n<p>\n  Acelyrin said Tang Capital held 8.8% of its outstanding common stock. \n</p>\n<p>\n  Tang Capital didn't immediately respond to a request for comment issued through LinkedIn. \n</p>\n<p>\n  Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount. \n</p>\n<p>\n  Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at $3 a share. \n</p>\n<p>\n  Concentra's all-cash proposal, which includes a right to receive 80% of proceeds from any out-license or disposition of Acelyrin's development programs or intellectual property, came after Acelyrin agreed earlier in the month to merge with Alumis in an all-stock deal that is expected to close in the second quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 13, 2025 08:15 ET (12:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2519350938","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519350938","pubTimestamp":1741868100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.Acelyrin said Tang Capital held 8.8% of its outstanding common stock.Tang Capital didn't immediately respond to a request for comment issued through LinkedIn.Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount.Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLRN":"Acelyrin, Inc.","ALMS":"Alumis Inc.","BK4007":"制药"},"translate_title":"Tang Capital Partners增持Acelyrin采用毒丸计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":0.9,"SLRN":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company. \n\n\n  The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock. \n\n\n  Acelyrin said Tang Capital held 8.8% of its outstanding common stock. \n\n\n  Tang Capital didn't immediately respond to a request for comment issued through LinkedIn. \n\n\n  Poison pills, also called shareholder-rights plans, are legal maneuvers that make it hard for shareholders to build their stakes beyond a set point by triggering an option for others to buy more shares at a discount. \n\n\n  Acelyrin in February received an unsolicited indication of interest from Concentra Biosciences, a portfolio company under Tang Capital Management, for an acquisition at $3 a share. \n\n\n  Concentra's all-cash proposal, which includes a right to receive 80% of proceeds from any out-license or disposition of Acelyrin's development programs or intellectual property, came after Acelyrin agreed earlier in the month to merge with Alumis in an all-stock deal that is expected to close in the second quarter. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 08:15 ET (12:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2519350938"}